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Abstract: Obesity is a global health threat. OECD reported that more than half (52%) of the adult population 
in the European Union is overweight or obese.  Obesity and obesity-related co-morbidities have deep negative 
effects on morbidity, mortality, professional and personal quality of life. Health-care costs represent a negative 
impact of this disease, with an associated economic cost of 100 billion US$ per year in the United States. The 
most prescribed drugs for obesity treatment worldwide are orlistat, and phentermine/topiramate extended release, while 
the major prescribed drug for the same disease in the US are exenatide and dapagliflozin. The so far developed drugs, 
targeting weight loss, have a long history of malignant secondary effects. There is still a lack of efficient and safe drugs to 
treat obesity and related metabolic complications since in many cases cure cannot be reached by bariatric surgery or 
healthy lifestyle habits. Terrestrial and aquatic organisms are a promising source of valuable, bioactive compounds, often 
with interest for human health. Some of the natural compounds or organisms have been used for centuries by humans as 
traditional medicine foods. In this review, we give insights into the adipose tissue function and development, and the 
progress in traditional anti-obesity pharmacotherapy. A major focus is to highlight the state of the art of natural 
compounds with anti-obesity properties and their potential as candidates for drug development; an overview is given 
about natural compounds derived from different marine animal sources, cyanobacteria, marine phytoplankton, fungus or 
plants. 
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1. INTRODUCTION 
 Obesity is a global health hazard associated with health 
problems such as hypertension, high cholesterol, diabetes, 
cardiovascular diseases, sleep apnea, respiratory problems 
(asthma), musculoskeletal diseases (arthritis) and some 
forms of cancer [1]. In the last 20 years, the percentage of 
obesity has nearly doubled in many European countries. The 
highest rates of obese adults are found in Mexico, followed 
by New Zealand and the United States, representing more 
than one third of the population, whereas in Asian countries 
the rates are between 2 and 4% (OECD, 2014). Healthy 
lifestyle promotion and lifestyle changes are preventive and 
straightforward. However, a large percentage of the world’s 
population may not be able to depend on this methodology 
alone, when treating obesity.  
 Obesity, as a metabolic failure causing disease, has had 
some compelling evidence suggesting more morbidity than 
smoking or alcoholism and pointing it as a leading cause of 
preventable death in the United States [2]. Diet, exercise, 
drug therapy, bariatric surgery or combinations of these are 
the current used methods to treat and prevent obesity [3]. 
Changes in diet and exercise can be an unreliable method,  
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ultimately resulting in regain of lost weight.  
 Bariatric surgery, used for patients with morbid obesity 
(Body Mass Index ≥ 40) is an invasive method with history 
of after-surgery complications. Bariatric surgery has been 
proven to be efficient in sustained weight loss, glycemic 
control and improved blood pressure and lipid profile. 
Although a big effort has been done to reduce surgical risk 
and recovery times, this technique still is a very invasive and 
expensive method with serious metabolic complications [4]. 
 Throughout history, pharmaceutical companies have 
been unable to develop safe and effective anti-obesity drugs, 
with numerous cases of drugs with several hazardous side 
effects, as for the intracranial bleeding and strokes associated 
caused by phenylpropanolamine [5] and heart attacks, 
hypertension and sudden deaths on people under dietary 
supplements containing ephedra alkaloids [6]. Despite the 
increasing need, the only anti-obesity drugs approved by 
both the food and drug administration (FDA) and the 
European Medicines Agency (EMA) are orlistat, 
phentermine/topiramate extended release, exenatide and 
dapagliflozin. Orlistat is a powerful inhibitor of lipases from 
both the stomach and intestines, derived from lipstatin, a 
natural product of the bacterium Streptomyces toxytricini [7].  
Preventing  the absorption of fat from the diet, it reduces the 
caloric intake, which combined with lifestyle changes has 
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in a weight reduction of 5-10% of body weight [8]. 
Phentermine/topiramate extended release acts by 
noradrenergic and GABAergic activation, leading to appetite 
suppression. Exenatide is a medication for the treatment of 
type 2 diabetes mellitus (T2DM), acting by increasing 
insulin sensitivity. Dapagliflozin is a synthetic analog of 
phlorizin, responsible for the inhibition of glucose reuptake 
in nephron. New approaches for the development of new 
anti-obesity drugs are needed based on a better 
understanding of molecular and metabolic pathways on 
lipogenesis.  
 Adipocytes, playing an important role as regulators of 
whole-body metabolism and homeostasis, originate from 
precursor cells [9]. Obesity, at the cellular level, is 
manifested as increase in the adipocyte cell size 
(hypertrophy) and cell number (hyperplasia) increase and 
both of these processes are largely dependent on the 
regulation of adipocyte differentiation [10].  
2. The adipose tissue 
2.1. Dynamics of the adipose tissue 
The perception of the adipose tissue changed 
markedly from simple fat storing cells to hormone-secreting 
cells with impact on the whole-body metabolism, energy 
metabolism in distant tissues, and sensitivity regulation 
towards insulin signaling.  Nowadays, it is recognized that 
the adipose tissue has crucial roles in thermogenesis, 
lactation, immune responses, endocrine regulation and 
energy provision. The tissue is composed of many cell types, 
as endothelial cells, hematocytes, pericytes, pre-adipocytes, 
macrophages and other immune cells [11]. However, in 
mammals, the adipose tissue is mainly constituted by two 
morphologically and physiologically very different types of 
cells: white adipocytes are cells with a single cytoplasmic 
lipid droplet and a squeezed nucleus, whereas brown 
adipocytes are polygonal cells with a round nucleus, several 
cytoplasmic lipid droplets and numerous large mitochondria. 
These two types of cells also differ in their distribution in the 
human body: white adipocytes are mostly found in 
subcutaneous (under the skin) and visceral depots (near 
internal organs), while brown adipocytes are found in 
visceral depots and near the aorta [12]. Brown adipose tissue 
(BAT) is exclusive to mammals and recognized as an 
evolutionary advantage, since it is specialized in body 
temperature maintenance, allowing mammals to survive 
during cold stress. This function is mediated by uncoupling 
protein-1 (UCP1) in the mitochondria [13], an exclusive 
protein of the BAT. Scientists also consider a third type of 
adipose tissue, which is under intense investigation, but its 
origin and function remaining unclear. Beige adipocytes are 
regions in the white adipose tissue containing brown or 
brown-like adipocytes [14]. This intermediate type of 
adipose tissue is thought to have different origins than the 
brown adipose tissue : they originate from white adipocytes 
with the expression of positive regulatory domain containing 
16 (PRDM16), a transcriptional modulator required for 
thermogenesis [14], when under β3-adrenergic stimulation, 
chronic activation of Peroxisome proliferator-activated 
receptor gamma (PPARγ) or adaptation to cold response 
[15]. It was previously known that the adipose tissue 
responds to physiological and environmental stimuli, due to 
its high density in nerve fibers in contact with adipocytes, 
allowing it to interfere with the nervous system [16]. The 
appearance of brown adipocytes itself (browning 
phenomenon) has been observed after adrenergic stimulus or 
cold exposure, derived from a direct transformation of white 
adipocytes into brown adipocytes (white-to-brown 
transdifferentiation) [12, 17]. This shows  the inherent 
plasticity of this important tissue and has a big impact on 
understanding obesity and its prevention, since it is accepted 
that individuals with more brown adipose tissue are more 
resistant to obesity and T2DM [18]. 
A special kind of adipocyte differentiation occurs 
during pregnancy and lactation. In female mice subcutaneous 
depots can transform into milk-secreting glands by adipo-
epithelial transdifferentiation [19]. This enhances the 
plasticity of this complex organ: the ability to reversibly 
differentiate into morphological and physiological different 
cells. Adipocytes have also been known to possess endocrine 
functions, secreting important hormones and adipokines 
which are considered to be important regulators of the 
whole-body metabolism. Leptin was the first characterized 
hormone to be secreted by the adipose tissue [20]. This 
hormone is produced by the obese (ob) gene and regulates 
energy homeostasis through binding to the leptin receptor 
(LEPR) in the hypothalamus. Leptin regulates appetite and 
food uptake, further directed by anorexigenic (appetite 
suppressing) or orexigenic (appetite stimulating) 
neuropeptides. On the one hand, when the adipose tissue 
decreases in mass, leptin levels decline and neuropeptide Y 
levels rise, leading to higher food intake [21]. Weight gain 
increases the adipokine levels, resulting in decreased food 
intake.  Through this feedback mechanism, leptin regulates 
adipose tissue mass. Pivotal roles of this hormone have been 
described also for the regulation of the reproductive, 
cognitive or immune system, and related autoimmune 
disorders, bone metabolism or hematopoiesis.  Other 
hormones produced by adipocytes are for example 
adiponectin or resistin. Adiponectin acts on the regulation of 
many physiological processes as glucose and lipid 
metabolism [22]. Resistin, mainly produced by monocytes 
and macrophages within the adipose tissue, is involved in the 
pathogenesis of insulin resistance [23,24]. 
The adipose tissue is crucial for a well-functioning 
metabolism and characterized as a complex organ due to its 
inherent plasticity, its ability to increase or decrease the 
number of constituent cells, and its transdifferentiation 
potential. 
2.2. The Metabolic Disease 
 Obesity is a complex metabolic disorder, characterized 
by the accumulation of fat in different body regions, due to a 
positive energy balance. Metabolic complications of obesity 
are T2DM, cardiovascular disease or cancer.   
 Interaction between genetic, behavioural and 
environmental factors has been proven to lead to obesity. 
Excessive nutrient intake, lack of exercise and genetic 
susceptibility are established as the main causes of obesity 
[25]. However, some endocrine disrupting chemicals, such 
as phthalates, bisphenol A and alkylphenols, are suspected to 
contribute to a high prevalence of obesity or developing 
obesity [26, 27]. Interestingly, associations exist between gut 
microbiota composition and obesity. The mechanisms 
through which these microbes exert their anti-obesity effects 
are still unclear. However, links have been made between 
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two distinct phyla of bacteria: the phylum Firmicutes is 
associated with obesity, whereas the phylum Bacteroidetes is 
associated with weight loss. Furthermore, the transplant of 
microbiota from obese or western diet-fed mice to lean mice 
resulted in weight gain [28]. 
 At the cellular level, obesity is manifested as increase of 
the cell size (hypertrophy) or the cell number (hyperplasia) 
and both processes are largely dependent on the regulation of 
adipocyte differentiation [10]. Adipocytes do not only store 
lipids, but, as mentioned before, also control the sensitivity 
towards insulin signalling and secrete hormones with long 
range effects involved in energy metabolism in distant 
tissues. Today, adipocytes are recognized as critical 
regulators of the whole-body metabolism [29].  
 The adipocyte plasticity is critical for insulin sensitivity 
and overall metabolic health.  Consequently, disturbances of 
adipocyte regulation are the origin of some metabolic 
diseases such as T2DM. However, T2DM and obesity are 
not exclusively correlated. Some obese people are diabetic, 
but a big percentage of the population is characterized as 
non-diabetic obese people, identified as metabolically 
healthy obese [30]. Metabolically healthy obese people have 
well-functioning adipocytes and thus lower mortality risks. 
The correlation commonly seen between obesity and T2DM 
is based on insulin resistance, characterized by cells that 
become resistant to the effects of insulin leading to glucose 
uptake. Physiological transformations of the adipose tissue, 
in particular adipocyte hypertrophy, as a result of obesity, 
adipocyte death and adipocyte stress result in increasing 
adipocyte remnants that need absorption by specialized cells 
as macrophages. Chronic deposition of these remnants 
causes therefore the chronic deposition of macrophages in 
the adipose tissue, which finally causes inflammation [31]. 
The higher presence of macrophages lead to higher content 
in cytokines in the obese adipose tissue; Furthermore, 
circulation of free fatty acids (FFAs) and FFAs depots in 
non-adipose tissues, as muscles, can also contribute to 
insulin resistance through the release of chemoattractant 
proteins [32]. Cytokines as  tumour necrosis factor-α 
(TNFα), interleukin-6 (IL-6), interleukin-1α (IL-1α) and 
interferon gamma (IFNγ) are potent inhibitors of cellular 
differentiation of adipocytes and lead to insulin resistance in 
mature adipocytes [33]. Cytokines, and in particular TNFα, 
are potent inhibitors of adipocyte differentiation via the 
PPARγ receptor, and lead to decreased triglyceride 
deposition and higher fatty acid level. Resulting 
consequences are ectopic lipid deposition and impaired 
glucose transport, which ultimately cause insulin resistance 
in mature adipocytes or muscle cells. Significantly reduced 
insulin receptor substrate 1 (IRS-1) and protein kinase B 
(PKB) phosphorylation levels were observed in adipocytes 
from patients with T2DM. Concomitantly, high levels of 
pro-inflammatory cytokines (IL-6, nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB)) were 
detected [34]. Nitric oxide released by macrophages may as 
well be responsible for increasing the susceptibility of 
adipocytes to gain insulin resistance [35].  
 Metabolic complications like T2DM may also be a 
consequence of other stimuli resulting from the expanding 
adipose tissue microenvironment. Hypoxia, due to the rapid 
expansion, leads to higher levels of fatty acids and products 
of cell death, which causes the migration of innate and 
adaptive immune cells, and finally inflammation of the 
adipose tissue [36]. Hence, inflammatory conditions due to 
adipose tissue expansion is the underlying cause to T2DM 
development and further consequences [37, 38]. 
 Obesity has further been linked with a series of cancers. 
Hormone dependent cancers as postmenopausal breast and 
ovarian cancers can be more frequent with high body weight 
and high fat index, since adipokines increase with adipose 
tissue mass and present pro-inflammatory activities.  Leptin 
exerts its activity through the leptin receptor, and 
inactivation of this receptor inhibits the proliferation and 
viability of human breast cancer cell lines [39]. The 
association between obesity and cancer was also 
demonstrated in adipocytes in vitro, glucose and fatty acids 
modulated the secretion of growth factor and cytokine, 
which in turn induced the proliferation of cancer cells [40]. 
 Even though there is little information about behavioural 
and obesity profiles, certain neurotransmitters are linked 
with this disease. Neurotransmitters as dopamine and 
norepinephrine have been found to modulate appetite and 
food intake. The relationship between the stimuli to higher or 
lowered food intake is thought to be the underlying 
mechanism. Dopamine has been particularly studied, and 
modulates food intake altering the food reward via the meso-
limbic circuitry of the brain [41]. Blockers of dopamine D2 
receptors result in increases of appetite and weight gain [42], 
while drugs that increase brain dopamine concentration 
present anorexigenic (appetite supressing) properties [43, 
44]. Food intake can be mediated as well by the endogenous 
levels of norepinephrine. Increases in norepinephrine  will 
lead to lowered food intake, [45] and serotonin and 
norepinephrine reuptake inhibitors induce satiety and 
effectively reduce the accumulation of abdominal fat [46]. 
High intake of calories increases noradrenergic turnover in 
peripheral tissues, causing elevated norepinephrine plasma 
level. The availability of norepinephrine transporter is 
decreased in the thalamus of obese individuals, supporting a 
link between noradrenergic dysfunction and norepinephrine 
levels in obesity [47].  
 Moreover, physical activity is also an important regulator 
of obesity via alteration of neurotransmitter level or 
inflammatory cytokines. Decreases in bodily activity (e.g. 
sedentary lifestyle) can lead to lowered noradrenergic levels, 
causing weight gain. Cardiorespiratory fitness was 
demonstrated to help preventing by decreasing inflammation 
and by protecting against adrenergic desensitization. 
Inflammatory cytokines were described to desensitize β-
adrenergic receptors to their ligands by elevating G protein–
coupled receptor kinase-2 (GRK-2) [48]. Several studies that 
reported weight loss, either through hypocaloric diet, 
exercise or liposuction, observed the reduction of the levels 
of circulating cytokines, as IL-6 and TNF-α, due to the  
decrease in adipose tissue mass [49, 50]. Also, 
neurohormones as catecholamines, adenosine and dopamine, 
which are higher during exercise, have the ability to inhibit 
pro-inflammatory functions of macrophages [51, 52]. 
2.3. Adipose tissue development 
 White adipose tissue is the main energy reserve in higher 
eukaryotes, in contrast to brown adipose tissue which 
dissipates energy through thermogenesis. White adipocytes 
are crucial to energy mobilization during energy deprivation. 
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When the energy intake is greater than the energy outflow, 
the adipose tissue expands. The growth of adipose tissue can 
result from an increase in adipocyte size (hypertrophy), 
adipocyte number (hyperplasia) or both [10]. Hypertrophy 
and hyperplasia are mainly determined by the number of 
differentiated adipocytes since the same content of lipids can 
either be stored in in few, big or in many, small adipocytes. 
The differentiation and proliferation of pre-adipocytes are 
the main factors determining the adipose tissue mass.  
 The adipose tissue derives from pluripotent mesenchymal 
stem cells. These cells have the ability to undergo 
differentiation into adipocytes, myocytes, chondrocytes and 
osteocytes [53] depending on the stimuli received. 
Differentiation into adipocytes requires passage through a 
pre-adipocyte stage, which, under appropriate conditions, 
will originate mature adipocytes. Pre-adipocyte proliferation 
occurs through clonal expansion and represents the initial 
steps towards adipogenesis, determining the number of 
mature adipocytes throughout adulthood [54]. During 
proliferation, some genes are significantly up-regulated as 
cyclin B2, cyclin D1 and cyclin E1, proliferating cell nuclear 
antigen (PCNA) and the insulin-like growth factor-1 (IGF-1) 
that is a potent activator of the protein kinase B (Akt) 
pathway that leads to cell growth and proliferation.  
 Adipocyte differentiation is induced by agents such as 
insulin or adrenergic mediators (epinephrine, cyclic 
adenosine monophosphate (cAMP)). Insulin acts through the 
activation of the IGF-R signaling pathway, which alters the 
expression of the sterol regulatory element-binding protein-1 
(SREBP-1) and results in the stimulation of glucose 
transporter type 4 (GLUT-4) - mediated glucose uptake and 
lipid synthesis. Increases of the cAMP, lead to 
phosphorylation of the cAMP response element-binding 
protein (CREB) that activates the expression of endogenous 
CCAAT/enhancer binding protein-α (C/EBP-α), a 
transcription factor crucial for adipocyte differentiation and 
lipid synthesis and accumulation. PPARγ is an important 
nuclear receptor with an active role in the regulation of 
adipogenesis, stimulating the expression of target genes 
involved in adipocyte differentiation and increased lipid 
storage [55]. During differentiation, pre-adipocytes lose their 
fibroblastic morphology, start to accumulate triglycerides in 
their characteristic lipid droplets, and acquire the appearance 
and metabolic features of mature adipocytes [56]. 
 Model cell culture systems have been vital in obesity 
studies. Pre-adipocyte cell lines, as 3T3-F442A and 3T3-L1, 
were first established as a valid model system in the 
laboratory of Green [56]. Both were originally developed by 
clonal expansion from murine Swiss 3T3 embryo cells and 
became a standard for studying pre-adipocyte differentiation, 
due to its efficiency to differentiate from fibroblasts to 
adipocytes. 
 To trigger the cascade of cell differentiation, protocols 
have been developed for effective in vitro differentiation. At 
the point of growth arrest, cells can be exposed to a cocktail 
composed of differentiation inducing agents. For the 
complete differentiation of the cell line 3T3-L1, an 
appropriate and effective cocktail has been established 
containing insulin, dexamethasone, and 3-isobutyl-1-
methylxanthine (IBMX) [57]. Insulin acts through the 
activation of the IGF-R signaling pathway; dexamethasone 
acts through the glucocorticoid signaling pathway; IBMX is 
an agent used to elevate the cellular cAMP.  
3. Anti-obesity Pharmacotherapy 
 As outlined before, obesity is a complex metabolic 
disease with no single cause or cure. Over the years many 
drugs have been proposed to treat or prevent obesity. During 
the long history of anti-obesity pharmacotherapy many drugs 
displayed a wide range of dangerous side-effects. 
 Anti-obesity drug development should focus on using a 
safe and effective drug regimen with a proper combination of 
improved diet and exercise, in order to attain a reasonable 
and sustainable reduction of body weight. For a drug to be 
approved in the treatment of obesity by the FDA it requires 
that the difference in mean weight loss between the drug and 
the placebo groups is at least 5% for at least 1 year and 
statistically significant, and that the proportion of subjects 
who lose at least 5% of baseline body weight in the active 
product group is at least 35% and is approximately the 
double of the proportion in the placebo-treated group [58]. 
Drug development for the treatment and prevention of 
obesity should focus on long-term treatments, hence 
ensuring long term efficacy and safety. Obesity, like 
hypertension, requires long-term control and treatment. FDA 
and EMA approved drugs still require the thoroughly 
analysis by the clinician of the benefits and risks’ balance. 
 As of December 2013, four drugs have been approved by 
both the FDA and the EMA for chronic weight management 
and obesity complications: orlistat (Alli®, GlaxoSmithKline; 
Xenical®, Roche), phentermine/topiramate extended release 
(Qsymia®, Vivus), exenatide (Byetta®, Bydureon®, Bristol-
Myers Squibb) and dapagliflozin (Farxiga®, Forxiga®, 
Bristol-Myers Squibb and AstraZeneca)). The FDA has also 
approved lorcaserin (Belviq®, Arena Pharmaceuticals), 
pramlintide (Symlin®, Amylin Pharmaceuticals) and 
phentermine (Qnexa®, Vivus), for the long-term treatment 
of obesity in 2012. Phentermine and lorcaserin are two 
appetite suppressants used for the treatment of obesity 
through noradrenergic activation. Pramlintide is the synthetic 
analogue of amylin that promotes satiety and inhibits the 
secretion of glucagon. However, EMA has rejected these 
drugs due to limited efficacy, carcinogenic and teratogenic 
potential, cardiovascular events and cognitive impairment, 
considering that their side-effects would not outweigh their 
benefits. In the following, we present some of the short-term 
and long-term drugs approved by the FDA/EMA and some 
alternative medications for the treatment and prevention of 
obesity. The drugs usually applied in obesity treatment can 
be mainly divided in three groups: drugs suppressing 
appetite, drugs increasing insulin sensitivity, drugs targeting 
sodium/glucose co-transporters and drugs decreasing lipid 
absorption. 
3.1. Drugs suppressing appetite 
 Noradrenergic drugs, acting by suppressing appetite, are 
FDA-approved for the short-term (less than 12 weeks) 
treatment of obesity. Phentermine is the most widely 
prescribed obesity medication in the United States [59]. 
Phentermine is used as a short-term treatment for obesity 
that acts by stimulating the anorexic signalling in the 
hypothalamus or the dopamine receptor in the hippocampus. 
Diethylpropion is another noradrenergic drug for the short-
term treatment of obesity with a similar adverse effect and 
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weight loss profile to phentermine but less commonly 
prescribed [59]. Common adverse effects of this group of 
drugs are listed in Table 1. Lorcaserin, a highly selective 
monoaminergic neurotransmitter 5-hydroxytryptamine2C 
receptor agonist, acts by appetite suppression and is used for 
the long-term treatment of obesity. This drug was FDA 
approved in 2012, after the results of clinical trials 
demonstrated decreases in blood pressure, total and low 
density lipoprotein (LDL)-cholesterol and triglycerides [60]. 
Another approach on treating obesity is combination therapy. 
Phentermine/topiramate-ER is a noradrenergic and GABA-
receptor activator, kainate/AMPA glutamate receptor 
inhibitor, ultimately causing appetite suppression. Other 
medications had a potential for obesity treatment or 
prevention. Fluoxetine, a serotonin selective reuptake 
inhibitor used for the treatment of depression, was found to 
promote weight loss up to six months, but not in a long-term 
manner [61].  
 Zonisamide, an antiepileptic medication, was also seen to 
induce weight loss. It is known to modulate GABAergic and 
glutamatergic neurotransmission and has anorexia as a lateral 
effect. However, its mechanism of action is yet to be 
described. In combination with bupropion, a weak 
norepinephrine-dopamine reuptake inhibitor, Empatic® 
(Orexigen Therapeutics) is in phase II trials [62]. 
3.2. Drugs increasing insulin sensitivity 
 Another route for anti-obesity drug development is for 
insulin sensitivity improvement, since insulin resistance has 
been largely described in obese individuals. Metformin is a 
short-term treatment for individuals with T2DM. The drug 
produced small sustained weight losses, primarily by 
suppressing glucose production by the liver and decreasing 
episodes of hyperglycaemia [63]. Two developed drugs are 
described to act on glycaemic modulation that ultimately 
leads to recovering insulin sensitivity and to improve the 
metabolic complications. Pramlintide, a synthetic analogue 
of human amylin, is subscribed for patients with type I and II 
diabetes [64, 65]. Amylin is a hormone that decelerates 
gastric emptying and promotes satiety via hypothalamic 
receptors, by inhibiting the secretion of glucagon. Its 
analogue was seen to promote weight loss in a similar way. 
Exenatide is an analogue of the hormone glucagon-like 
peptide-1, an antihyperglycaemic hormone, which also 
targets on gastric emptying delay and suppression of appetite 
[64]. As Byetta®, it was approved by the FDA in 2005 and 
the EMA in 2006 for the long term treatment of T2DM. 
Although this group of drugs improve weight loss, the 
blocking of gluconeogenesis in the liver can lead to adverse 
effects as muscle pain due to increased lactic acidosis (Table 
1).  
3.3. Drugs inhibiting sodium/glucose co-transporters 
 Another class of compounds are sodium/glucose co-
transporter 2 (SGLT2) inhibitors.  Dapagliflozin (Forxiga®) 
is a synthetic analogue of the natural compound phlorizin, 
which competes with glucose in the proximal tubule of the 
nephron, thereby decreasing glucose reuptake and the levels 
of glucose in the blood stream [66, 67].  This compound, 
approved in 2014 by the FDA, has shown beneficial effects 
in weight reduction and the improvement of insulin 
sensitivity. Other analogues of these natural compounds are 
to be launched and to be developed.  
3.4. Drugs decreasing lipid absorption 
 In the group lipid absorption decreasing drugs, the main 
anti-obesity drug is presented. Orlistat is used for the long-
term treatment of obesity, approved by the FDA early in 
1999 and the EMA in 2006. Orlistat effectively inhibits 
pancreatic and gastric lipases, and stops the breakdown of 
dietary lipids into fatty acids and monoglycerides. As a 
result, approximately 32% of the ingested fat is excreted 
compared to 5% during administration of placebo [68]. Even 
though orlistat has been occasionally associated with acute 
kidney injury, which can occur due to disturbances in fat 
absorption, it is vital to carbohydrate metabolism and has 
been widely and safely used as a consensual anti-obesity 
drug. 
3.5. Future approaches 
 The approach on drug discovery can focus on peripheral 
or central targets, although a combined approach can lead to 
more efficient strategies [69]. Even though European 
Organizations seem skeptical towards appetite suppressants 
as lorcaserin [70] due to its lateral effects, many submissions 
for drug approval are being delivered as a form of 
combination therapy.  
 It was believed that inhibitors of adipogenesis could be a 
potential anti-obesity therapy. However, it has been seen in 
mice and humans that this could lead to a poor metabolic 
health state, since limiting adipocyte expansion is associated 
with insulin resistance, leading to T2DM [71]. Danforth 
(2000) proposed that when adipose tissue stops 
accommodating excess calorie intake due to expansion or 
differentiation impairment can result in lipodystrophy; this 
process decreases leptin levels and adipose tissue displays 
degenerative conditions. Later on, Dubois and co-workers 
[72] found evidence that subjects with T2DM larger 
adipocytes when compared with adipocytes of non-diabetic 
individuals (adipocyte hypertrophy), while having the same 
number of adipocytes, and that insulin sensitivity is inversely 
related to fat cell size. Recruitment of pre-adipocytes in 
adipose tissue is able to prevent obesity-related metabolic 
complications, rather than restricting adipogenesis [73]. In 
this context, the stimulation of adipocyte hyperplasia could 
be beneficial to accommodate the surplus energy and to 
reduce the obesity associated co-morbidities as T2DM or 
cardiac disease.  
 Some published papers described activities through UCP 
modulation, an important protein involved in thermogenesis 
and a possible therapeutic target for obesity. Brown adipose 
tissue in mammals, specialized in energy dissipation for 
thermogenesis, has also been considered as a target for anti-
obesity treatment. It has been established that the 
noradrenergic system is also able to activate BAT, through 
increase of catecholamines or β-adrenergic receptors 
activation [74]. 
 As described before, the availability of norepinephrine at 
noradrenergic synapses can be regulated by motivated 
behaviors that might be important contributions to the 
development of obesity. Therefore, the norepinephrine 
transporter in the cortical and subcortical brain regions may 
also be a therapeutic target for drug development as 
stimulants and antidepressants. Since dopamine has also 
been seen differentially present in obese and non-obese 
individuals, drug development focusing on the modulation of 
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dopamine levels and reward circuits could be a beneficial 
strategy.  
 Recently, a new approach on development of anti-obesity 
drug has been proposed, targeting the purinergic system that 
might also be involved in BAT activation. Adenosine, as an 
endogenous ligand of a class of purinergic receptors, is able 
to effectively activate human and murine brown adipocytes 
[75].  The treatment with adenosine A2A agonists results in 
higher glucose tolerance and less body fat. A higher gene 
expression of A2A receptors leads to decreased adipocyte 
hypertrophy, reduced expression of inflammatory cytokines 
and increased expression of BAT marker [75]. Thus, the so-
called browning of the adipose tissue might be a new 
approach for developing innovative obesity therapies.  
4. Approved natural compound for disease treatment 
 The potential of natural compounds on drug development 
has been widely explored and proven to be a reliable and 
fruitful source. Natural compounds from organisms as 
primary metabolites (steroids, nucleosides, etc.), vitamins, 
hormones, protein fragments, herbal mixtures and 
polyamines fall into the category of natural product drugs, 
even if they are synthetically produced, whereas compounds 
inspired from a natural product template, but synthetically 
derived are considered natural product derived drugs.  
Semi-synthetic drugs of natural origin had a natural 
compound as a template, and currently marketed with some 
modifications and synthetically produced. Synthetic drugs 
don’t share similarities with known natural compounds and 
are therefore synthetically derived. In 2010, around 10% of 
the drugs on the market were unaltered natural products, 
29% derived from natural products, known as semi-
synthetic, and the rest (61%) was composed with drugs of 
synthetic origin [76]. The unmodified natural products 
tended to decrease due to the prevalent introduction of many 
new synthetic drugs [77]. Between 2000 and 2013, 25% (14 
out of the 56) approved drugs with natural origin were 
unaltered natural products, while the majority were semi-
synthetic natural products [78]. Between 2008 and 2013, a 
total of 25 natural product and natural product derived drugs 
were approved, representing 18% of the 100 NP and NP-
derived compounds reviewed in [78]. These numbers 
underline the importance of natural product discovery. 
Important therapeutic areas for new natural products and 
semi-synthetic natural compounds are oncology and 
infectious diseases, which make up to 64% of the natural 
drug targets. 
 The first two marine-derived natural products that have 
been developed into drug substances were cytarabine 
(Cytosar-U®, Depocyt®), a synthetic pyrimidine nucleoside 
last approved by the EMA in 2001 for the treatment of 
cancer, and vidarabine, a synthetic purine nucleoside with 
antiviral properties, both developed from natural compounds 
from the Carribbean sponge Tethya crypta [79]. About 6 
years later, ziconotide (Prialt®), was approved for the 
treatment of moderate to severe pain. Ziconotide is the 
synthetic formula of a 25-amino acid peptide, originally 
isolated from the venom of the marine snail Conus magus 
[80]. Trabectedin (Yondelis®) is a marine-derived product, 
approved by the EMA in 2003 for the treatment of soft tissue 
sarcoma and ovarian carcinoma, isolated from the tunicate 
Ecteinascidia turbinate found in the Caribbean and 
Mediterranean seas [81]. In 2010, a natural product derived 
drug was approved by the FDA and EMA for the treatment 
of metastatic breast cancer: halichondrin B, a polyether 
isolated from the marine sponge Halichondria okadai [82].  
 Natural product discovery for the treatment of 
cardiovascular and metabolic diseases has also a high 
demand of drug development. This group includes the 
SGLT2 inhibitors described before (Section 3), derived from 
the natural product phlorizin, a polyphenol. Synthetic 
compounds derived from phlorizin were shown to be more 
effective and selective, mainly due to the reduced 
degradation by glucosidase enzymes and increased intestinal 
absorption. Derived drugs developed are dapagliflozin  and 
canagliflozin (Invokana®, Janssen Pharmaceuticals, Inc), 
approved by the EMA. Many other analogues are currently 
in phase III and phase II clinical trials. 
 Another  compound for patients with classical Hodgkin’s 
lymphoma, peripheral T-cell lymphoma, diffuse large B-cell 
lymphoma or systemic anaplastic large cell lymphoma was 
approved by the FDA in 2011 and by the EMA in 2012: 
brentuximab vedotin (Adcetris™) [83]. This compound is a 
novel anti-body drug conjugate composed by a chimeric 
monoclonal anti-CD30 antibody, cAC10, directing this 
compound specifically into CD30-positive malignancies, and 
a cathepsin-cleavable linker as a backbone to carry 
monomethyl auristatin E (MMAE) [84]. MMAE is a 
synthetic compound derived from dolastatin 10 that was first 
isolated from the sea hare Dolabella auricularia with 
described potent antineoplastic activity [85]. The compound 
was later shown to be produced by the cyanobacteria 
Symploca hydnoides and Lyngbya majuscula, which are part 
of the sea hare’s diet [86]. 
5. Natural compounds with anti-obesity properties 
 Many natural compounds have been studied that 
demonstrated interesting activities for the prevention and 
treatment of obesity and related metabolic complications as 
T2DM and cardiovascular disease. Most of the research 
employed in vitro methodologies (e.g. modulation of the 
differentiation of 3T3-L1 cell line), in vivo techniques (e.g. 
adipose mass tissue decreases in mice or rats), or direct 
enzymatic assays (e.g. lipase activity screening).  
 In our bibliographic research, we noted that the largest 
group of origin for anti-obesity natural compounds is plants, 
followed by marine algae, fungi and animals (summarized in 
Figure 1). 
 Some of the latest literature describing anti-obesity 
natural products has shown promising activities, through 
direct hormone sensitive lipase or pancreatic lipase 
inhibition. Xylarenals A and B, two sesquiterpenoids, 
isolated from the ascomycete Xylaria persicaria, were found 
to be selective antagonists for the neuropeptide Y5 [87], 
which is a receptor found in peripheral and central nervous 
system, involved in mediating food intake and body weight 
[88]. Fucoxanthin, a carotenoid from Undaria pinnatifida 
[89] and evodiamine, an alkaloid traditionally used in China 
as a “fat burner” [90] induced UCP-1 expression, and 
phytochemicals from the leaves of Peucedanum japonicum 
Thunb increased the expression of the UCP-3 gene in muscle 
[91].  
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 The majority of the natural compounds with described 
anti-obesity properties described so far are phenols or 
polyphenols (13 out of 53, 25%) as shown in Figure 2. 
Phenols and polyphenols are naturally present in a wide 
variety of organisms; cathechins from green tea leaves, 
licochalcone A from the root of Glycyrrhiza glabra, tyrosol 
from Rhodiola crenulata and dehydrodiconiferyl alcohol 
from Cucurbita moschata have anti-obesity activities. 
Terpenes are a representative group of natural compounds, 
with both neurohormonal activity, as the xylarenals A and B 
from Xylaria persicaria, and adipose tissue mass regulation, 
as for the ursolic acid from Sambucus australis Cham. 
Diarylheptanoids and polyketides, as moccasin and 
ankaflavin from the mold Monascus sp., are two distinct 
small classes of secondary metabolites that together compose 
about 6% of the compounds with anti-obesity activity.  
 The origin of natural organisms with anti-obesity 
activities, either through their extracts, fractions or isolated 
compounds, is presented as their geographical distribution 
(Figure 3). Some are endemic to certain continents or 
countries, while others are present in many ecosystems: up to 
19 out of 100 natural organisms described are ubiquitous, 
such as the marine algae Hematococcus pluvialis, producer 
of astaxanthin, and Salicornia herbacea. The greatest source 
of natural compound discovery is Asia, known for their 
ancient traditional medicine. Most of the compounds are 
derived from South (India) or East Asia (Japan, China, 
Korea), which might correlate with the lowered incidence of 
obesity in these countries: obese individuals represent 2 to 
4% of the adult population in these countries, whereas in 
countries like Mexico, New Zealand and the United States, 
they represent about 18% (OECD, 2014). 
 
 In the next sections, we explore compounds produced by 
different organism structured as follows: marine animals, 
marine algae, cyanobacteria, fungi, and plants.  
5.1. From marine animal origin 
 Animals are a important part of human’s diets all over 
the world due to their valuable nutritional components. Their 
pharmaceutical potential has been explored and numerous 
compounds may have important interactions with the human 
organism, both nutritionally and metabolically.  
5.1.1. PUFA´s and crude oils from fish and crustacean 
 Cholecystokinin (CCK), a brain-gut peptide, inhibits 
food intake in rats through the activation of peripheral CCK-
1 receptors [92]. Recent research indicated that peptides 
from protein hydrolysates of shrimp (Penaeus aztecus) heads 
were an effective agent, which stimulated the CCK release in 
intestinal cancer cells [93]. 
 Nutritional studies indicate that diets high in content of 
saturated fats lead to increases in adipose tissue mass. In 
contrast, polyunsaturated fatty acids (PUFA) consumption, 
lead to decreasing deposition of adipose tissue. In particular, 
two long chain n-3 PUFA, eicosapentaenoic acid (EPA; 20:5 
n-3) and docosahexaenoic acid (DHA, 22:6 n-3) from marine 
fish oil were studied in mice and 3T3-L1 pre-adipocytes, and 
increased mitochondrial genes and PPARγ in white adipose 
tissue, which suggested upregulation of mitochondrial 
biogenesis and induction of β-oxidation [94]. Further studies 
of these two PUFA’s revealed that short-term 
supplementation leads to significant increases of adiponectin 
that correlates with higher fatty acid breakdown, without 
anti-inflammatory effects [95, 96]. More recently, these two 
PUFA’s were shown to decrease lipid and cholesterol 
biosynthesis in the liver of dietary obese mice, pointing them 
as a reliable therapeutic approach for non-alcoholic fatty 
liver disease (NAFLD) [97]. 
 Oils with high content of n-3 PUFA’s from marine 
zooplankton have been studied, in particular from the 
copepod Calanus finmarchicus. Supplementation of crude 
Calanus finmarchicus oil showed improved glucose 
tolerance and decreases in abdominal tissue mass and 
adipose tissue inflammation in diet-induced obese mice [98]. 
However, Calanus oil is composed by several other 
components, other than PUFA’s (roughly 80%) such as 
monounsaturated fats, antioxidants as astaxanthin, and 
phytosterols. PUFA’s of Calanus oil are bound to aliphatic 
long-chain monounsaturated alcohols as wax esters. Hoper 
and co-workers [99] demonstrated that wax esters had the 
same beneficial effects as crude Calanus oil, reducing body 
weight gain, abdominal fat, liver triacylglycerol and 
macrophage infiltration in fat depots. Proinflammatory genes 
were downregulated, whereas adiponectin expression was 
upregulated, which provided evidence that PUFA’s cannot 
be accounted exclusively for its beneficial metabolic effects; 
in fact, wax esters are an important component of these oils 
[99].  
Glucosamine is a derivate of chitin, a biopolymer from the 
exoskeleton of marine invertebrate animals, used as a 
nutritional supplement and for numerous medical 
applications due to its effects on cell proliferation and 
osteoblastic differentiation [100]. Recently, derivatives of 
glucosamine were found to inhibit adipocyte differentiation, 
possibly via AMP-activated protein kinase, which regulates 
glucose and lipid homeostasis in adipocytes [100]. 
5.1.2. Marine sponges 
 Marine sponges have been a fruitful source of bioactive 
compounds. They are sessile filter feeders with highly 
effective defence mechanisms against viruses, bacteria or 
eukaryotic organisms, and with a high content in secondary 
metabolites [101]. Dysidine is a sesquiterpene quinone found 
in Hainan sponge Dysidea villosa in the Chinese South Sea. 
Its anti-obesity potential was studied in differentiated 3T3-
L1 cells and resulted in the increased deposition of GLUT4 
in the cellular membrane [102]; this correlates to higher 
insulin sensitivity and could be a potential compound for the 
treatment of T2DM. Heterofibrins are a group of bioactive 
compounds from the southern Australian marine sponge 
Spongia (Heterofibria) sp. and were found to be inhibitors of 
lipid-droplet formation in the A431 fibroblast cell line [103]. 
Phorbaketal A is a compound, which  promotes osteogenic 
differentiation, through the transcriptional coactivator with 
PDZ-binding motif (TAZ), involved in cell differentiation 
and proliferation [104]. This compound, isolated from the 
marine sponge Phorbas sp. was found to block adipogenic 
differentiation in the fibroblastic C3H10T1/2 cell line, by 
increasing the expression of TAZ [105]. 
 Another compound from marine sponges was found to be 
a possible alternative to orlistat, one of the most common 
pharmaceuticals for obesity treatment. Methyl xestospongic 
is an ester from the marine sponge Xestospongia testudinaria 
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that showed inhibitory activity against pancreatic lipase, the 
essential enzyme for lipid digestion in the intestinal tract 
[106].  
 Bioactive compounds from marine sponges could also be 
a major tool for studying the metabolism of prescription 
drugs. A series of 4-methylenesteroid derivatives isolated 
from Theonella sp. are novel pregnane-X-receptor (PXR) 
modulators [107]. PXR is a gene involved in the metabolism 
of xenobiotics and endobiotics as bilirubin, bile acids, 
glucose and lipids. Studying the molecular basis of its 
interactions with external compounds could be of great 
importance for therapeutic drug development for human 
diseases as T2DM and obesity. 
5.1.3. Tunicates 
 Another novel group of natural compounds are 
meridianins (A-G), marine indole alkaloids isolated from the 
tunicate Aplidium meridianum. Meridianins are potent kinase 
inhibitors [108] with described anti-cancer activity [109]. In 
particular, derivatives of meridianin C showed strong 
inhibition of lipid accumulation during 3T3-L1 pre-
adipocyte differentiation and lowered leptin expression 
[110]. Even though this compound was found to be 
cytotoxic, it is highly interesting to explore this compound 
on a mechanistic level since it influenced important 
differentiation pathways as C/EBP-α, PPARγ and fatty acid 
synthase [110].  
 Resuming, marine animals are a promising source of 
compounds with possible anti-obesity properties. Bioactive 
compounds are mostly identified from marine sponges, 
followed by crustaceans, fish oils and tunicates (Figure 4).  
5.2. From Fungi 
 Organisms classified as Fungi belong to a kingdom that 
includes eukaryotic organisms as yeasts, moulds and 
mushrooms. Organisms in this category have also become 
very attractive for their medicinal and health-stimulating 
properties.  
 Monascus  is genus of mold used as a traditional food 
fungus widely consumed in East Asia as health supplements 
and for their pigments that can be used as natural colorants 
[111]. The effects of the aminoacids L-tryptophan and L-
leucine ethyl ester derivatives have shown to decrease serum 
total cholesterol and triglyceride levels in mice in vivo. In in 
vitro assays, high inhibitory activities were observed against 
lipoprotein lipase and 3-hydroxy-3-methyl-glutaryl-CoA 
reductase (HMG-coA reductase), an important enzyme in the 
metabolic pathway that produces cholesterol [112]. 
Monascus-fermented products are increasing in number, and 
red mold dioscorea (RMD, known as Monascus purpureus-
fermented Disocorea batatas) had mild hypolipidemic 
activities [113]. The isolated compounds from the 
Monascus-fermented product, moccasin and ankaflavin, are 
two polyketides thought to be responsible for the bioactivity 
of red mold dioscorea, since they inhibited adipose tissue 
differentiation and lipogenesis in vitro [113].  
 Deep sea water has been a part of many research studies 
for therapeutic approaches on lifestyles diseases. An 
experimental group of obese mice (ob/ob) was treated with 
deep sea water with high hardness for 84 days. As result, the 
body weight gain decreased significantly, as well as plasma 
glucose levels compared to the control group. The deep sea 
water treatment decreased plasma protein levels of resistin, 
increased plasma levels of adiponectin and GLUT4 in 
skeletal muscle, which demonstrated the potential of deep 
sea water to attenuate T2DM, obesity and cardiovascular 
diseases [114]. The interesting effect of deep sea water 
(≥200m in depth) could be due to its high purity, abundant 
nutrients and minerals; it has already been useful in the 
agriculture, pharmaceutical and cosmetic industries [115, 
116]. Following this study, deep sea water was used to raise 
RMD, in order to assess if deep sea water could enhance the 
anti-obesity potential of moccasin and ankaflavin. Both in 
vitro and in vivo higher beneficial effects of deep sea water-
cultured RMD were observed, compared to ultra-pure water-
cultured RMD [117].  
 Xylarenals A and B are two novel sesquiterpenoids, 
isolated from the ascomycete Xylaria persicaria, that are 
selective antagonists for the neuropeptide Y5 [87], a receptor 
found in peripheral and central nervous system, and involved 
in mediating food intake and body weight [88]. Ternatin is a 
cyclic heptapeptide isolated from the mushroom Coriolus 
versicolor. Treatment of diet-induced obese mice suppressed 
the increase in body weight and fat accumulation [118]. A 
study of structure-activity relationship of ternatin derivatives 
was performed and showed that a naturally occurring amino 
acid (β-OH-D-Leu7) is a potent inhibitor of fat accumulation 
in 3T3-L1 adipocytes [119]. A methanol extract from the 
mushroom Phellinus linteus fruiting body exhibited a high 
lipase inhibitory activity, which is a highly important 
mechanistic potential for anti-obesity drug development 
[120]. The bioactive compound responsible is yet to be 
elucidated. Dietary intake of powdered whole Panellus 
serotinus (Mukitake) reportedly attenuated NAFLD in obese, 
diabetic db/db mice [121]. When fractions of the extracts of 
Mukitake extracts were studied, the water-soluble extract 
and the ethanol-soluble extract had beneficial effects in the 
db/db mice and significantly reduced hepatic triglyceride 
content. The water soluble Mukitake extract decreased the 
serum level of monocyte chemoattractant protein-1, which is 
known to be responsible for insulin resistance, while the 
ethanol soluble Mukitake extract lead to increased levels of 
circulating adiponectin [122]. Consumption of Grifola 
frondosa is very common in East Asia, as a traditional 
beneficial medicine food. Polysaccharides from Grifola 
frondosa, also known as Maitake, exerted hypoglycaemic 
activity in HepG2 cells  [123]. Glucose uptake was enhanced 
in a dose-dependent manner and the insulin receptor protein 
in the cell membrane was activated. In another study using 
high-fat diet fed and streptozotocin-induced hyperglycaemic 
mice, a non-polar fraction of Grifola frondosa significantly 
lowered blood glucose level, serum total cholesterol, and 
showed a strong anti-α-glucosidase activity, an enzyme that 
acts on the breakdown of starch and disaccharides [124]. 
Recently, a water extract of a mushroom used in traditional 
Chinese medicine (Ganoderma lucidum) was demonstrated 
to reduce body weight, inflammation and insulin resistance; 
the obesity induced gut dysbiosis (ratio of Bateroidetes to 
Firmicutes) was reversed in mice, and a high molecular 
weight polysaccharide (>300 kDa) isolated from this extract 
was stated as the possible responsible compounds for the 
anti-obesity and microbiota-modulating effect [125]. 
 Most of the described mushrooms are part of the East 
Asian cuisine. Interestingly, mushrooms are a reliable source 
of anti-obesity compounds and might be a favourable 
Short Running Title of the Article Journal Name, 2014, Vol. 0, No. 0    9 
addition to Western food habits, where the obesity epidemic 
is more prevalent.  
5.3. From Marine Algae 
 Marine algae are geographically widespread organisms 
that can be divided in two groups: micro- and macroalgae 
(seaweeds). Macroalgae are benthic organisms present in 
seawater or brackish water and comprise approximately 6000 
species. They are divided into three main classes green 
(chlorophytes), red (rhodophytes) and brown (phaeophytes) 
algae. The traditional consumption of seaweed in eastern 
Asia may be linked with the lower incidence of metabolic 
syndrome. Tororokombu, for example, is a traditional 
Japanese food from the 1620s, made by edible kelp, a type of 
large seaweeds. The non-shaved version has powerful anti-
obesity effects decreasing serum triglyceride levels [126]. 
The main compound in seaweeds is fibre, with varying 
content of soluble and non-soluble fibres dependent from 
species. Fibres in diet can prevent metabolic syndromes 
associated to obesity (T2DM and cardiovascular 
complications). Fibres are typically low in fat and lipids, and 
very rich in nutrients as magnesium and polyphenols. 
Interesting compounds as fucoxanthin, fucosterol or 
polyphenols are recognized as nutraceutical compounds from 
seaweeds. Some of them interact with peroxisome 
proliferator-activated receptors (PPARs), which are a 
superfamily of nuclear hormone receptors of ligand-activated 
transcription factors. They are widely studied targets for 
treatment of T2DM and dyslipidaemia, and isotypes as 
PPARα and PPARγ are associated with fatty acid oxidation, 
and lipid synthesis, respectively. An Undaria pinnatifida-
derived fucoxanthin-enriched ethanoic extract effectively 
reduced body and abdominal white adipose tissue weights, 
plasma and hepatic triglyceride and cholesterol in high-fat 
diet fed mice [127].  As we explored before (Section 2.1), 
one promising molecular target for anti-obesogenic drug 
discovery could be the induction of UCP-1 in white adipose 
tissue. Genomic studies actually showed that fucoxantin 
induced UCP-1 expression in mitochondria of abdominal 
white adipose tissue, which caused the oxidation of fatty 
acids and thermogenesis [89].  
 Some compounds are geographically ubiquitous and 
found in many trophic levels of the food chain, due to 
bioaccumulation. Astaxanthin, a xantophyll carotenoid with 
anti-oxidant and anti-inflammatory properties, mainly 
produced by the marine algae Hematococcus pluvialis, but 
also found in many krill species as Euphausia pacifica, 
Euphausia superba and Pandalus borealis, the yeast 
Xanthophyllomyces dendrorhous, and in salmon, trout and 
crustaceans. Astaxanthin has been reported to have anti-
obesity properties, it inhibited increases in body weight and 
adipose tissue mass in high-fat diet fed mice and lowered 
liver and plasma triglyceride level and total cholesterol 
[128]. More recently, a part of the molecular mechanism was 
elucidated for astaxanthin effects; increased insulin 
sensitivity, enhanced the autophosphorylation of insulin 
receptor-β, the GLUT-4 translocation in skeletal muscle and 
the IRS-1 phosphatidylinositol 3-kinase step, a pathway 
responsible for glucose uptake, lipogenesis and glycogen 
synthesis [129].  
 Eisenia bicyclis is a marine brown alga from the Pacific 
coast around Korea and Japan. Its methanolic extract, 
composed mainly by phlorotannins (as eckol, bieckol, 
fucofuroeckol A, 7-phloroeckol, dioxindehydroeckol and 
phlorofucofuroeckol A), inhibited pancreatic lipase [130]. 
Purified phlorotannins suppressed the differentiation of 3T3-
L1 adipocytes in a dose–dependent manner, without any 
toxic effects, and 6,6′-bieckol was responsible for the most 
significant results [131]. 
 The anti-obesity potential of Laminaria japonica 
Areshoung, a traditional Korean marine brown algae, was 
evaluated in Sprague-Dawley male rats, and caused 
decreasing body weight gain, serum and hepatic lipid levels 
and, at the cellular level, decreasing number of lipid droplets 
and adipocyte size [132].   
 Numerous compounds from the brown alga Ecklonia 
cava have been isolated and studied for activity. The 
phloroglucinol derivative, 1-(3′,5′-dihydroxyphenoxy)-7-
(2″,4″,6-trihydroxyphenoxy)-2,4,9-trihydroxydibenzo-1,4-
dioxin [133] and dioxinodehydroeckol [134] inhibited lipid 
accumulation during adipogenesis and downregulated genes 
associated with adipogenesis in 3T3-L1 cells. Phlorotannins 
were isolated from this brown alga, reduced the lipid 
accumulation and glucose consumption in 3T3-L1 
adipocytes and suppressed adipogenic transcription factors 
as PPARγ and SREBP-1 [135]. 
 Fucosterol, isolated from Ecklonia stolonifera, also 
inhibited adipocyte differentiation and lipid formation, since 
it inhibits expression of PPARγ and C/EBPα in a 
concentration-dependent manner, without any cytotoxicity 
[136]. 
 Sargassum is a genus of approximately 250 species of 
brown algae that has been at the centre of obesity research. 
In 2008, the plastoquinones, sargaquinoic acid and 
sargahydroquinoic acid, isolated from Sargassum yezoense 
were identified as novel PPARα/γ dual agonists, with a 
binding affinity even higher than the specific PPARγ agonist 
troglitazone. In the 3T3-L1 cells, exposure to both 
compounds increased adipocyte differentiation and mRNA 
expression of adipogenic marker genes [137]. In contrast, 
extracts of a further Sargassum species (Sargassum 
thunbergii) were studied in 3T3-L1 fibroblasts, and were 
responsible for the inhibition of lipid accumulation and 
suppression of adipogenesis genetic markers [138]. Some 
monoglactosyldiacylglycerols from the brown alga 
Sargassum horneri inhibited also triglyceride accumulation 
and free fatty acid levels in 3T3-L1 adipocytes [139]. 
 Fucoidan is a group of sulphated polysaccharides from 
marine brown algae that have various medicinal applications 
[140, 141]. The main active compounds are L-fucose (sugar) 
and sulphate ester groups, which showed impairment of 3T3-
L1 pre-adipocyte differentiation [140]. The inhibitory effect 
of this compound was later elucidated: fucoidan increased  
hormone sensitive lipase in differentiated 3T3-L1 treated-
adipocytes, suggesting stimulation of lipolysis [142]. 
 Polysaccharides from Ulva lactuva decreased blood 
glucose level in adult rats, due to a strong inhibition of 
enzymes related to starch digestion [143]. 
 Food for male Wistar rat was supplemented with dried 
Ulva ohnoi (UO) and Derbesia tenuissima (DT), after 16 
weeks of a corn starch-rich diet or a high-carbohydrate, high-
fat diet with drinking water supplemented with fructose. 
Supplementation with UO lowered final body fat mass and 
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improved glucose metabolism and insulin sensitivity. In 
contrast, supplementation with DT did not change the total 
body fat mass but decreased plasma triglycerides and total 
cholesterol [144].  
 Siphonaxanthin, a xanthophyll common to green algae 
species, was studied in vitro and in vivo, and suppressed pre-
adipocyte differentiation in 3T3-L1 cells, and lowered white 
adipose tissue weights in diabetic KK-Ay mice [145].  
5.4. From cyanobacteria 
 Some strains of cyanobacteria are commercially available 
for consumption due to their beneficial properties to human 
health, e.g. Arthrospira, Nostoc and Aphanizomenon [146]. 
Cyanobacteria contain bioactive and beneficial components 
as carotenoids, γ-linoleic acid, phycocyanin, fibers, and plant 
sterols [147]. Arthrospira, previously known as Spirulina, is 
a filamentous cyanobacteria belonging to the class III 
(Oscillatoriales) which is usually found in high salt-alkaline 
water bodies. Its use as a traditional food in Central Africa, 
and studies that demonstrated its beneficial effects on human 
health has led to its consumption worldwide. The therapeutic 
effects, generally comprising the major three species 
Arthrospira platensis, Arthrospira maxima, Arthrospira 
fusiformis,  include anti-hypercholesterolemia, anti-
hyperglycerolemia, anti-inflammatory, anti-tumor and anti-
viral activities; it is also protective of cardiovascular 
diseases, mainly due to its hypolipidemic, anti-oxidant and 
anti-inflammatory activities [148]. Many preclinical studies 
have been performed in various animal models and 
demonstrated a hypolipidemic activity of Arthrospira. 
Arthrospira is well recognized for its high protein content 
and its richness in minerals, essential fatty acids and 
carotenoids, as β-carotene, astaxanthin and canthaxanthin 
[149], phycobiliproteins as c-phycocyanin phenolics as 
synapic, chlorogenic and caffeic acids, and anti-oxidant 
vitamins as Vitamin E  . 
 Studies revealed that supplementation of the diet with 
Arthospira species, significantly ameliorated the 
hyperlipidemic profiles of high fat/high cholesterol diet, high 
fructose and high sucrose diets, and carbon tetrachloride-
induced fatty livers in rats and mice, lowering hepatic 
cholesterol and triglyceride levels [150–154]. 
 These promising results were confirmed in human 
clinical trials, where supplementation with Arthrospira 
species resulted in decreases of plasma triglyceride 
concentrations and of the ratio of high and low density 
lipoprotein in subjects with T2DM. Arthrospira also presents 
a high content of γ-linoleic acid (around 1.3%), which is 
frequently used to treat rheumatoid arthritis, atopic eczema, 
acute respiratory distress syndrome, cancer, and asthma, and 
to improve plasma lipid profiles [155].   
 Recent studies reported that the in vitro and in vivo anti-
diabetic effect of Arthrospira could be from the active 
component phycocyanin, a phycobiliprotein that lowered 
body weight, serum and liver triglyceride content  and 
fasting plasma glucose in KK-Ay mice (KK mice strain with 
the yellow obese gene Ay), most likely by enhancement of 
insulin sensitivity [156]. However, the inherent high 
polysaccharide content itself has the capacity of lowering 
insulin and glucose blood levels and to promote cholesterol 
elimination in feces [157].  
 The major component of Spirulina, phycocyanin, 
accounting for 14% of the cyanobacteria’s dry weight [158], 
has been reported to be a potent anti-inflammatory  agent, 
which abolished the TNF-α response in Kupffer cells from 
mouse liver after induction of thyroid calorigenesis [159], 
and reduced inflammatory cell infiltration and colonic 
damage in rats with acetic acid induced colitis [160]. Other 
studies described phycocyanin as a powerful antioxidant 
agent with neuroprotective effects, able to scavenge reactive 
oxygen species [161].  
 Diet supplementation with Nostoc commune var 
sphaeroides Kützing (N. commune) demonstrated 
hypocholesterolemic activity in mice, reduced intestinal 
cholesterol absorption and stimulated fecal sterol excretion 
[162]. Its lipid extract significantly lowered the expression of 
HMG-CoA reductase, a key enzyme for cholesterol 
biosynthesis, and the levels of mature forms of SREBP-1 and 
SREBP-2, leading to a decreased mRNA expression of genes 
involved in the cholesterol and fatty acid metabolism [163]. 
Furthermore, the lipid extract of N. commune reduced the 
mRNA expression of proinflammatory genes, evaluating the 
levels of proinflammatory mediators as TNF-α, COX-2, IL-
1β, IL-6 in RAW 264.7 macrophages in a dose-dependent 
manner [164]. The anti-inflammatory activity may be 
mediated, at least in part, by inhibiting the NF-κB pathway 
in order to decrease the production of proinflammatory 
mediators [147]. 
 Cyanobacteria have a strong potential to possess further 
unknown bioactive compounds with anti-obesity, anti-
inflammatory or anti-oxidant properties. Safety assessments 
of certain cyanobacteria strains are now performed, in order 
to evaluate if dietary supplementation of cyanobacteria may 
be consumed without toxic side-effects [165]. 
5.5. From plants 
 As was elucidated in the Table 2, plants are the main 
source of natural compounds with anti-obesity properties. In 
around 15% of the studies, the whole plant was used to 
screen for activity (stem, leaves and flowering parts); in 
other studies the anti-obesity activity assessment focused on 
a single part of the plant as seeds, leaves, fruits or roots. 
Furthermore, formulations exist from different plants as for 
the Egyptian herbal mixture formulation, composed of T. 
chebula, Senae, rhubarb, black cumin, aniseed, fennel and 
liquorice. Such mixture formulation normalized lipid profiles 
in diet induced-obese rats and lowered body weight and 
metabolic complications of obesity, as defective antioxidant 
stability and high values of insulin resistance parameters 
[166].  
 Known beneficial plants as ginseng are known to contain 
a high variety of bioactive saponins and glycosides with 
foaming properties. Two major compounds saponins, 
protopanaxadiol and protopanaxatriol, were tested in diet-
induced obese Sprague-Dawley rats and reduced body 
weight, total food intake, fat contents and serum cholesterol 
and leptin level. Neurohomone levels were also assessed in 
this experiment and revealed that mRNA expression of 
orexigenic neuropeptide Y was significantly decreased with 
both protopanaxadiol and protopanaxatriol, whereas the 
mRNA level of anorexigenic cholecystokinin increased, 
compared to the high fat diet group [167]. These results 
suggest that saponins from ginseng have anti-obesity 
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properties by modulating hypothalamic neuropeptides and 
inhibiting energy input, through the alteration of important 
targets for anti-obesity drug development. Activity guided 
fractionation of extracts of Vitis coignetiae Pulliat resulted in 
the isolation of resveratrol, that was found to have similar 
activities, resulting in the inhibition of neuropeptide Y and 
agouti-related protein, two hypothalamic neuropeptides that 
stimulate food intake [168]. Resveratrol also inhibits fatty 
acid synthase and activates Sirt-1; alteration of both targets 
leads to decreased adipogenesis [169] 
 Galangin is a flavonol glycoside isolated from Alpinia 
galanga Willd, a native plant cultivated in Malaysia, India, 
Indochina and Indonesia, used as a traditional remedy for 
many diseases as obesity and T2DM. It was shown to have, 
in fact, in vitro pancreatic lipase inhibitory activity. In in 
vivo experiments with female albino rats, galangin inhibited 
increases in body weight and decreased serum lipids, lipid 
peroxidation and accumulation of hepatic triglycerides [170]. 
Ursolic acid is a pentacyclic titerpenoid. When adult male 
Swiss mice were treated with ursolic acid extracted from the 
aerial parts of Sambucus australis Cham. from Brazil, body 
weights decreased, as well as visceral adiposity and level of 
blood glucose relative to their controls: amylase and lipase 
activities also decreased, whereas plasma leptin levels were 
higher [171]. A water soluble extract prepared from the stem 
parts of Cucurbita moschata, a species of pumpkin, exerted 
anti-obesity activities in high fat diet-induced obese mice, 
suppressing body weight and fat storage, while food intake 
did not change. The water extract was protective against the 
development of fatty liver disease, and increased hepatic β-
oxidation and decreased lipogenic genes as SREBP-1 [172]. 
In 2012, the responsible compound for the anti-obesity 
activity of Cucurbita moschata was elucidated, after solvent 
fractionation. Dehydrodiconiferyl alcohol (DHCA), a 
polyphenol, significantly decreased the expression of 
adipogenic marker genes and the lipid accumulation, while 
maintaining cell viability [173]. Treatment with DHCA also 
suppressed the proliferation of  3T3-L1 cells and primary 
mouse embryonic fibroblasts, lowering the expression of cell 
cycle marker genes, as cyclin-dependent kinase 2 [173]. 
 Spergularia marina is a flowering plant popular in South 
Korea, recognized as a beneficial source of amino acids, 
vitamins and minerals. Treatment of 3T3-L1 fibroblasts with 
S. marina whole extract significantly reduced lipid 
accumulation and decreased adipogenic gene levels and was 
further seen to increase osteoblastogenic differentiation in 
MC3T3-L1 pre-osteoblasts, increasing levels of 
osteoblastogenesis markers [174]. Another plant extract was 
also used to study both adipogenesis and osteoblastogenesis. 
Salicornia herbacea extract reduced lipid accumulation and 
inhibited gene expression of PPARγ, C/EBP-α and SREBP-
1. On the other hand, activity of alkaline phosphatase, an 
osteoblastogenic marker, was increased by 120% at a 
concentration of 100 μg/mL in differentiating osteoblasts 
[175].  
 Indole-3-carbinol is a compound present in various 
vegetables. The compound was tested in male C57BL/6 mice 
treated with a high fat diet and decreased body weight and 
epididymal adipose tissue weight. Mice from the high fat 
diet group treated with indole-3-carbinol also had improved 
glucose tolerance and modulated expression of adipokines 
and adipogenic-associated genes, as PPARγ [176].  
 Shikonin (5,6-dihydroxyflavone-7-glucuronic acid), the 
main compound of the Japanese plant Lithospermum 
erythrorhizon, was tested in the differentiation of 3T3-L1 
adipocytes. It inhibited the formation of lipid droplets and 
accumulation of triglycerides and the expression of 
regulators of adipogenesis as SREBP-1C, PPARγ and 
C/EBP-α [177]. Using the same in vitro model system, the 
inner bark extract of the trees Populus balsamifera and Alnus 
incana were analysed. The extract of Alnus incana was a 
partial agonist towards PPARγ, while Populus balsamifera 
extracts significantly inhibited the adipogenesis, and acted as 
antagonist of PPARγ [178]. Tyrosol, a major bioactive 
phenolic compound from Rhodiola crenulata, disrupted the 
energy generation by the pentose phosphate pathway in 3T3-
L1 adipocytes, which led to the suppression of adipogenesis 
and lipid accumulation [179]. The Rhodiola extract also 
increased the superoxide dismutase activity in a dose-
dependent manner, resulting in lowered reactive oxygen 
species during adipogenesis [179].  
 The ethanol extract of Taraxacum officinale, also known 
as dandelion, was tested for its inhibitory potential against 
pancreatic lipase. In vitro studies showed inhibitory activities 
of pancreatic lipase in a dose dependent manner and in vivo 
studies confirmed inhibitions of plasma triglyceride levels 
after ingestion [180]. Ethanol extracts from flower buds of 
Splilanthes acmella also had an inhibitory activity towards 
pancreatic lipase in a concentration-dependent manner [181]. 
5.5.1. From fruits  
 Fruits are an important source of anti-obesity 
compounds. Fruits are part of the flowering plant and 
disseminate seeds for species propagation. Fruits have high 
contents of water, carbohydrates in the form of simple 
sugars, and minerals. In our bibliographic search, they 
represented around 9% of the sources with anti-obesity 
properties, either through the whole fruit or identified 
bioactive compounds, identified as described in the 
following. 
 Chlorogenic acid, commonly found in apples, pears, 
tomatoes and blueberries, exhibited a significant anti-obesity 
activity lowering body weight, visceral fat mass, plasma 
leptin and insulin levels in high-fat diet induced-obese mice. 
Triglyceride content in adipose tissue was also significantly 
lowered, as well as the activity of fatty acid synthase, HMG- 
CoA reductase and acyl-CoA:cholesterol acyltransferase, 
while fatty acid β-oxidation and PPARα expression was 
increased in the liver. These results underline the complex 
interactions of anti-oxidants with the lipid metabolism and 
hints on mechanistic pathways towards its anti-obesity 
profile [182]. Evodiamine is an alkaloid from the fruits of 
Evodia rutaecarpa, a traditional Chinese medicine, known as 
a “fat burner”. In fact, its potential was confirmed to 
decrease body weight, perirenal and epididymal fat mass, 
and serum levels of free fatty acids, triglyceride and 
cholesterol in the liver [90]. More interestingly, evodiamine 
treatment significantly increased specific guanosine-5'-
triphosphate (GDP) binding in the mitochondria of brown 
adipose tissue, which is a modulator of UCP-1 [90]. Another 
study evaluated the effects of Psidium guajava puree, also 
known as pink guava, in high fat diet induced-obese rats. 
Pink guava puree reduced body weight, glucose levels, total 
cholesterol and systolic blood pressure, compared to control. 
Antioxidant enzymes, as glutathione peroxidase and 
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superoxide dismutase, had also higher activities after 
treatment of high fat diet induced-obese rats with pink guava 
[183]. 
 Mulberries, known for their antioxidant compounds, 
were analysed for anti-obesity activity. Their water extract 
reduced lipid accumulation, suppressed fatty acid synthesis 
and stimulated fatty acid oxidation in HepG2 cells. The 
suggested mechanism for the activity of mulberry water 
extract is via phosphorylation of adenosine monophosphate-
activated protein kinase [184]. In 2013, a study reported that 
1-deoxynojirimycin extracted from mulberries decreased 
visceral fat weight and the size of adipocytes in diet-induced 
obese mice and increased β-oxidation due to higher 
circulating levels of adiponectin [185]. Furthermore, 1-
deoxynojirimycin decreased glucose absorption in the 
intestinal cells, while at the hepatic level, the activity of 
glycolysis enzymes increased and the activity of 
gluconeogenesis enzymes decreased [186]. 
 Using cell lines as in vitro model system, 3T3-L1 cells 
were treated with raspberry ketone, a phenolic compound 
isolated from the red raspberry, in order to elucidate its 
mechanism; differentiated adipocytes showed increased 
lipolysis and secretion of adiponectin, which is involved in 
fatty acid breakdown [187]. Garcinia cambogia’s fruit 
extract had also potential as anti-obesity nutraceutical, since 
it inhibited lipid droplet accumulation, without affecting the 
differentiation of adipocytes [188].  
 The shell of the peanut (Arachis hypogaea), when 
extracted in 95% ethanol, had inhibitory activity against 
pancreatic lipase and lipoprotein lipase. Wistar rats treated 
with the peanut shell extract had increased fecal lipid 
excretion, which confirms the inhibitory activity on lipases 
[189].  
5.5.2. From roots 
 The physiological functions of roots are the absorption of 
water and inorganic nutrient and the storage of organic 
nutrients. Roots have symbiosis with bacteria and fungi, 
which may represent the ecological advantage of containing 
a high content of secondary metabolites and nutrients.  
 Prunetin, a known isoflavone found in peas, showed anti-
obesity properties, significantly reducing body weight gain 
in mice fed with a high fat diet, inhibiting the high fat diet-
induced upregulation of the expression of adipogenic genes 
and inducing expression of adiponectin receptors [190]. 
 Phytochemicals from ginger, as 6-gingerol, zerumbone 
and the rhizome extract of a plant of the ginger family, 
reduced significantly the increases in adipose tissue mass in 
high fat diet-induced obese mice and targeted the cholesterol 
metabolism and the fatty acid breakdown by increasing the 
activity of key enzymes [191]. Ursolic acid isolated from the 
roots of Actinidia arguta, also known as hardy kiwi, 
inhibited the increase of triacylglycerol levels after oral 
administration of a lipid emulsion in rats [192]. The authors 
discuss that the protective activity observed in this study 
might be attributed to the inhibition of lipid absorption in 
intestinal cells, possibly by inhibition of pancreatic lipase. 
 The benefits of phytochemicals like curcumin on human 
health have been intensively studied. Curcumin reduced 
chronic inflammation, which is associated with obesity. 
Curcumin ameliorated insulin resistance in genetically obese 
mice and diet-induced obese mice, and had significantly 
reduced macrophage infiltration within the white adipose 
tissue that links with lowered local inflammation [193]. 
Curcumin suppressed differentiation of 3T3-L1 pre-
adipocytes by reducing the number of mature adipocytes and 
fat content, assessed by Oil Red O staining [194]. Curcumin 
treatment also inhibited the mRNA expression of key 
adipogenesis genes as PPARγ and C/EBP-α. 
 Tanshinone IIA is an herbal compound, abundant in the 
root of Salvia miltiorrhiza, used in traditional Chinese 
medicine to treat cardiovascular diseases. Tanshinone exerts 
anti-oxidant and anti-inflammatory effects. It suppressed 
adipogenesis through inhibition of PPARγ in 3T3-L1 
adipocytes, and reduced adipose mass tissue and body 
weight, and improved glucose tolerance in high fat diet-
induced obese mice [195]. 
 Polygonum cuspidatum is a medicinal plant commonly 
used in East Asian countries. The n-butanol fraction of the 
Polygonum cuspidatum extract exerted significant inhibitory 
activities on adipogenesis in a dose-dependent manner, 
evidenced by the reduced formation of lipid droplets and 
decreased glycerol-3-phosphate dehydrogenase activity. 
Adipogenesis marker proteins and genes were also decreased 
[196]. 
 Licorice, a well-known sweet flavour, is the root of 
Glycyrrhiza glabra. After some studies described the 
metabolic benefits of liquorice extract, in 2014 the 
responsible compound was elucidated: 18β-glycyrrhetinic 
acid. It suppressed anadamide-induced 3T3-L1 adipocyte 
differentiation, a cannabinoid receptor type 1 agonist, and 
downregulated adipogenic genes and the protein levels of 
fatty acid synthase and stearoyl-CoA desaturase 1. The 
animal model confirmed these results, showing that 
supplementation with 18β-glycyrrhetinic acid resulted in 
decreases of body weight, fat weight and plasma lipid levels 
in high-fat diet induced obese mice  [197]. The anti-obesity 
properties of licochalcone A, a natural phenol also from the 
root of Glycyrrhiza glabra, were assessed in 3T3-L1 
adipocytes and resulted in reduced lipid accumulation and 
down regulation of the expression of key adipogenic genes 
and receptors [198]. The analysis in high-fat diet induced 
obese mice confirmed the anti-obesity effect of licochalcone 
A by decreasing their body weight and plasma triglyceride, 
and cholesterol level  [198].  
 1'-acetoxychavicol acetate is an ester naturally found in 
Alpinia galanga and Languas galangal, two plants from the 
ginger family used in Thai and Indonesian cuisine. The 
effects of this antioxidant were studied in 3T3-L1 adipocytes 
and lowered lipid accumulation through the down-regulation 
of PPARγ and C/EBP-α in the mature adipocytes. In high fat 
diet-fed rats 1'-acetoxychavicol acetate lowered the activity 
of glycerol-3-phosphate dehydrogenase, which is involved in 
carbohydrate and lipid metabolism. Steatohepatitis did not 
occur in the treated rats, which indicates that this compound 
may be preventive against metabolic  disease [199]. 
5.5.3. From leaves  
 Leaves represented around 13% of the sources of anti-
obesity compounds and around 23% of the compounds 
described from plants. Leaves are an important organ of 
vascular plants composed by the epidermis, the mesophyll 
tissue, where the chloroplasts are found, and veins. Leaves 
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are worldwide consumed as source of beverages as in herbal 
teas and recognized for their numerous and versatile benefits. 
Tea leaves are rich in tea chatechins, which are antioxidant 
phenols, e.g. gallocatechin gallate, catechin gallate and 
epigallocatechin gallate. Biosynthesis of important 
flavonoids also takes place in leaves, as for anthocyanin, 
which is increased under stress [200]. The prevalence of 
complex compounds in leaves is to be expected, since they 
are exposed to many environmental stresses as high 
irradiances, UV radiation, water stress and mechanical 
injury, as well as biotic stresses such as herbivory and 
pathogen attack. 
 Vernonia amygdalina is a small shrub typical from 
tropical Africa. Its leaf powder was added to the diet of diet-
induced obese rats  for 4 weeks and resulted in a decrease of 
body weight gain, serum triacylglycerol, serum and brain 
total cholesterol; effects were stronger than by the anti-
obesity drug orlistat also tested in this study [201]. 
Administration of pu-erh tea in rats with high fat diet-
induced obesity significantly reduced the total body weight, 
plasma total cholesterol, triglyceride concentrations and low-
density lipoprotein-cholesterol, suggesting an attenuating 
effect on fat levels and accumulation [202].  
 The leaves of Peucedanum japonicum Thunb (PJT) are 
traditionally consumed in Okinawa Island (Japan) due to its 
health benefits. The administration of powdered PJT 
inhibited high fat diet-induced obesity in mice [203] and 
phytochemicals present in the ethanol extract exerted 
promising activities in C57BL/6 mice. The ethanol extract 
decreased fat accumulation and adipocyte size, reduced 
serum and liver triglyceride concentrations and inhibited the 
overall obesity. The PJT ethanol extract also inhibited lipase 
activity in vitro and increased the expression of the UCP-3 
gene in muscle of high-fat diet-induced obese mice, which is 
involved in thermogenesis [91]. 
 The dichloromethane and ethyl acetate extracts of 
Murraya koenigii leaves, also known as curry tree, resulted 
in decreases of body weight, plasma total cholesterol and 
triglyceride levels in high fat diet induced obese rats [7]. An 
extract made from two herbs widely used in East Asia, 
Scutellariae Radix and Platycodi Radix, was used to confirm 
their anti-inflammatory, anti-hyperlipidemic and anti-obesity 
activities. Their common component, target herbal ingredient 
(THI), is thought to be responsible for these activities. High 
fat diet-induced obese mice were orally administered a daily 
dose of THI for 10 weeks, which caused a reduction of body 
weight, improved the glucose tolerance and total serum 
cholesterol level [204]. In vitro tests using 3T3-L1 showed 
that adipogenic transcription factors were down regulated by 
THI in a dose-dependent manner [204]. 
 The methanol extract of Dypsis lutescens leaves, also 
known as bamboo palm, showed specific in vitro inhibitory 
activity towards pancreatic lipase and lowered triglyceride 
accumulation in 3T3-L1 pre-adipocytes [205]. 
 Houttuynia cordata Thunb., also known as chameleon 
plant, is an East Asian flowering plant native, used in 
traditional medicine. The water extract from the leaves 
decreased obesity symptoms in corn oil-induced obese mice, 
as increased plasma triglyceride and glycerol levels [206]. 
 Maté tea, widely consumed in South America, Spain and 
Portugal produced from the leaves of Ilex paraguariensis, 
showed strong effects on porcine and human pancreatic 
lipase activity in vitro and also ameliorated the increases in 
body weight and unhealthy lipid profile of diet induced-
obese mice [207]. 
 Other herbal medicines from China, as Inchinko-to, 
Bofu-tsusho-san and Dai-saiko-to, are used as therapeutic or 
preventive agents for various diseases. Their health benefits 
were investigated on male mice fed with a high-fat diet. 
Diets supplemented with the herbal medicines resulted in 
lowered plasma lipid levels, Dai-saiko-to being the most 
beneficial [208]. 
 Nelumbo nucifera Gaertn. leaves, also known as sacred 
lotus, are used in Japan and China as a medicinal plant more 
recently to treat obesity. It reduced body weight, body lipid 
accumulation and activity of fatty acid synthase in diet-
induced C57BL/6 obese mice [209]. The pharmacology of  
the leave extract involved inhibitory activities of α-amylase 
and lipase, and stimulatory activities on the lipid metabolism 
and on mRNA expression of UCP-3 mRNA in diet-induced 
obese mice [210]. 
 Macrostemonoside A, a steroidal saponin isolated from 
Allium macrostemon Bung. bulbs, a traditional Chinese 
medicine, showed moderate inhibition of diet-induced 
increases of blood glucose, liver glycogen, serum total 
cholesterol and visceral fat accumulation [211].  
 Tea leaves are rich in tea chatechins, which are 
antioxidant phenols. Treatment with gallocatechin gallate 
and catechin gallate in rats for 23 days resulted in lowered 
activity of enzymes related to hepatic fatty acid synthesis, as 
fatty acid synthase and malic enzyme, leading to decreases in 
hepatic triacylglycerols [212]. Epigallocatechin gallate 
exerted anti-adipogenic effects through the WNT/β-catenin 
pathway, upregulating the nuclear level of β-catenin that 
leads to the downregulation of major adipogenic markers as  
PPARγ, C/EBP-α, fatty acid binding protein and fatty acid 
synthase [213].  
 Green tea originates from China and is made from the 
leaves of Camellia sinensi known for its high composition in 
antioxidants as phenols. Studies have shown that drinks 
supplemented with catechins and epigallocatechin gallate, 
two types of flavanols present in green tea, are effective 
against obesity, hypercholesterolemia and hyperglycemia 
[214]. Studies showed that treatment of 3T3-L1 adipocytes 
with green tea catechins increased the level of glycerol and 
free fatty acids released into the medium that correlates with 
enhanced lipolysis, but only in the presence of 
norepinephrine [215]. This shows that green tea catechins 
could have beneficial activities in a protein kinase A-
dependent pathway. 
 
5.5.4. From seeds 
 Seeds are embryonic plants, important for the 
reproduction of gymnosperm and angiosperm plants. They 
are enclosed in a protective outer layer named the seed coat 
and constituted by the embryo in the inside part. Within the 
seed, nutrients are stored for the growth of the embryo, 
which varies depending on the kind of plant. Seeds are a 
small part of the diet of humans in general, when compared 
to the dietary portion represented by animals, vegetables and 
fruits. Some antioxidants from seeds are extensively 
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described as secoisolariciresinol diglucoside, a lignan 
present in flax, sunflower, sesame and pumpkin seeds [216]. 
Flaxseed is one of the most commonly used seed in human 
diet, recognized as a supplement for its beneficial properties 
due to its high content of PUFAs, secoisolariciresinol 
diglucoside, phenolic acids and flavonoids. Phenolic 
compounds as other secondary metabolites are beneficial to 
the embryonic plant in their constitution in order to prevent 
degradation of fatty acids and other nutrients during seed 
storage [217]. 
 Ethanol extracts from seeds of Afromomum meleguetta 
had an inhibitory activity towards pancreatic lipase in a 
concentration-dependent manner [181]. Fermented soybean 
products have been established to be beneficial for general 
health.  
 Doenjang, a seasoning used in Korean cuisine, was tested 
in overweight human adults and found to reduce body 
weight and body fat mass, mainly visceral fat [218]. Linoleic 
acid, an omega-3 fatty acid, extracted from flaxseed oil was 
determined to be an effective modulator of inflammation and 
adipocyte dysfunction, with some of the inflammation 
markers lowered 70 to 80% with the flaxseed oil treatment 
[219].  
 A water infusion of Hunteria umbellata dried seeds is 
used in Nigerian folk medicine as an obesity and 
hyperlipidaemia management procedure. Oral doses of the 
aqueous seed extract, with combined pre-treatment with 
simvastatin, significantly reduced the weight gain pattern in 
induced hyperlididaemic rats [220].  
 Deglycosylation of soygerm isoflavones, through a 
process of fermentation by Bifidobacterium breve, results in 
the formation of aglycones (as daidzein, glycitein, genistein), 
which are strong inhibitory compounds of pancreatic lipase, 
both in a fermentation-time and dose-dependent manner. 
Oral administration of the fermented isoflavones in rats 
caused decreases in triglyceride plasma levels after 2 hours 
of administration, when compared to the oral administration 
of unfermented isoflavone group, establishing the potential 
of the fermented isoflavones as important lipid absorption 
suppressants  [221].  
 Kochujang, a seasoning used in korean cuisine, derived 
from fermentation of powdered red peppers and soybeans, 
rice syrup and rice flour for six months, has been reported to 
have several benefits both in vitro and in vivo. Its effects 
were tested in overweight men and women in a 12-week 
study. The kochujang-treated group showed a significant 
reduction in visceral fat, even though body weight did not 
change, and in serum triglycerides, compared to the placebo 
group [222].  
 Fenugreek seed extract was also found to reduce body 
weight gain in diet-induced obese mice. The major 
component of the extract, 4-hydroxyisoleucine, also 
decreased plasma triglyceride gain [223].  
 The anti-obesity potential of oligomeric and polymeric 
procyanidin fractions from grape seeds was assessed in 3T3-
L1 adipoyctes. Treatment resulted in lowered lipid 
accumulation, but not by lipolytic enzyme activity [224]. 
 Hippophae rhamnoides, also known as sea-buckthorn, is 
a species of flowering plant, native to dunes and sea cliffs in 
Europe and Asia. A study investigated the ability of its 
flavone extracts from the seed residues to regulate insulin 
and angiotensin levels. Mice fed with a high sucrose diet 
showed significant rises in systolic blood pressure, plasma 
insulin, triglycerides and activated angiotensin in heart and 
kidney, showing the anti-hypertensive and anti-
hyperinsulinemia potential of this plant [225]. 
 The seed extract of Nelumbo nucifera was also evaluated 
using 3T3-L1 pre-adipocytes and the treatment significantly 
inhibited pre-adipocyte differentiation, in a dose-dependent 
manner, without showing cytotoxicity [226].  
 The reported anti-obesity activities are summarized in 
Table 2, derived from various natural resources. Most of the 
observed effects relied on alteration of adipogenesis, food 
intake, pancreatic lipase activity, improvement of insulin 
sensitivity, increase of UCP mRNA expression, or anti-
inflammatory activities. Some studies specifically revealed 
benefits related to the metabolic complications of obesity, as 
NAFLD. As ameliorated obesity symptoms, we grouped 
results from in vivo experiments, mainly using rats and mice 
as the animal model. Effects in this group include decreases 
of body weight gain, plasma total cholesterol, or triglyceride 
concentrations in animals fed with high fat diets. 
CONCLUSION 
 The adipose tissue is a very dynamic organ, and involved in 
the regulation of the whole-body metabolism by secreting 
hormones and adipokines. Obesity is caused by an excess intake 
of calories and obesity is linked to various obesity-related co-
morbidities, e.g. T2DM, cardiovascular disease, chronic 
inflammation or others. Many potential drug targets exist for 
anti-obesity pharmacotherapy and the actually most used are 1) 
drugs suppressing appetite, 2) drugs reducing intestinal lipid 
absorption or 3) drugs increasing insulin sensitivity.  
 Many advances are taking place towards the development of 
drugs acting on specific targets for obesity treatment. Targets 
for obesity treatment do not include exclusively the adipose 
tissue. Promising drugs for weight control are focusing on 
pancreatic lipase inhibitors, modulation of appetite and obesity-
linked behaviour through anorexigenic neuropeptides, and on 
transdifferentiation of beige adipocytes through UCP activation. 
Drugs concerning the metabolic complications of obesity as 
chronic inflammation, T2DM, hypertension and cardiovascular 
disease, focus on the dynamics of adipocyte tissue for the 
improvement of insulin sensitivity and adipose tissue balance, 
as adipocyte differentiation modulators and SGLT-2 inhibitors 
blocking glucose reabsorption in the proximal tubule of the 
nephron.  
 Natural compounds are a major source of many promising 
candidates that have beneficial influence on either obesity or 
obesity-related co-morbidities. In this review, we highlighted 
many natural sources and natural described compounds that 
modulate many different anti-obesity targets, cementing natural 
derived drugs as a major tool not only for anti-cancer, anti-
microbial and anti-neurodegenerative drug development, but 
also as a big promise for many anti-obesity drugs. This review 
highlights the discovery of new bioactive compounds, generally 
from complex mixtures from natural resources. It is important to 
mention that most of the bioactive compounds will need further 
experiments for the study of underlying mechanism, but also of 
potential side effects and other safety issues. 
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 The further study of the molecular targets of natural anti-
obesity compounds with strong observed activities, offers a 
potential to discover new modulating compounds of several 
potential pathways for the treatment of this multifactorial 
disease. Even if not for drug development, natural dietary anti-
obesogenic phytochemicals may be used as nutraceuticals to 
help inverting the trend of an increasing incidence of obesity.  
An emerging trend exists for the consumption of functional 
foods produced by nutraceutical companies worldwide, in 
addition to the promotion of an active and healthy lifestyle. 
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